Literature DB >> 7648347

The antiphospholipid syndrome. Diagnosis, management, and pathogenesis.

E N Harris1.   

Abstract

Much more is known about the APLS than 15 yr ago, but more needs to be done. Clinically, major characteristics of the disorder have been defined, but the course of the disease and its relationship to other disorders, such as systemic lupus erythematosus (SLE), need to be defined. Good progress has been made in standardizing anticardiolipin and, to a lesser extent, LA. However, problems with interlaboratory and inter-assay variation need to be addressed. Doctors are getting a better idea of how to manage these patients with a view to preventing recurrences of thrombosis or pregnancy losses, but prospective studies are still desirable to give more definitive answers. Attention has turned to the pathogenesis of the disorder. It seems likely that antibodies mediate the clinical disorders with which they are associated, but the mechanisms by which this occurs still require further study.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7648347     DOI: 10.1007/BF02772247

Source DB:  PubMed          Journal:  Clin Rev Allergy Immunol        ISSN: 1080-0549            Impact factor:   8.667


  40 in total

1.  Special report. The Second International Anti-cardiolipin Standardization Workshop/the Kingston Anti-Phospholipid Antibody Study (KAPS) group.

Authors:  E N Harris
Journal:  Am J Clin Pathol       Date:  1990-10       Impact factor: 2.493

2.  Antiphospholipid antibodies and recurrent pregnancy loss: correlation between the activated partial thromboplastin time and antibodies against phosphatidylserine and cardiolipin.

Authors:  N S Rote; D Dostal-Johnson; D W Branch
Journal:  Am J Obstet Gynecol       Date:  1990-08       Impact factor: 8.661

3.  A reassessment of the antiphospholipid syndrome.

Authors:  E N Harris
Journal:  J Rheumatol       Date:  1990-06       Impact factor: 4.666

4.  Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.

Authors:  M Galli; P Comfurius; C Maassen; H C Hemker; M H de Baets; P J van Breda-Vriesman; T Barbui; R F Zwaal; E M Bevers
Journal:  Lancet       Date:  1990-06-30       Impact factor: 79.321

5.  Induction of phospholipid-binding antibodies in mice and rabbits by immunization with human beta 2 glycoprotein 1 or anticardiolipin antibodies alone.

Authors:  S S Pierangeli; E N Harris
Journal:  Clin Exp Immunol       Date:  1993-08       Impact factor: 4.330

6.  Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: beta 2-glycoprotein I (apolipoprotein H).

Authors:  H P McNeil; R J Simpson; C N Chesterman; S A Krilis
Journal:  Proc Natl Acad Sci U S A       Date:  1990-06       Impact factor: 11.205

7.  Induction of antiphospholipid autoantibodies by immunization with beta 2 glycoprotein I (apolipoprotein H).

Authors:  A E Gharavi; L R Sammaritano; J Wen; K B Elkon
Journal:  J Clin Invest       Date:  1992-09       Impact factor: 14.808

8.  Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience.

Authors:  D W Branch; R M Silver; J L Blackwell; J C Reading; J R Scott
Journal:  Obstet Gynecol       Date:  1992-10       Impact factor: 7.661

9.  Antibody to cardiolipin as a predictor of fetal distress or death in pregnant patients with systemic lupus erythematosus.

Authors:  M D Lockshin; M L Druzin; S Goei; T Qamar; M S Magid; L Jovanovic; M Ferenc
Journal:  N Engl J Med       Date:  1985-07-18       Impact factor: 91.245

10.  Beta 2-glycoprotein 1 (beta 2GP1) enhances cardiolipin binding activity but is not the antigen for antiphospholipid antibodies.

Authors:  S S Pierangeli; E N Harris; S A Davis; G DeLorenzo
Journal:  Br J Haematol       Date:  1992-11       Impact factor: 6.998

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.